Drug Chatter -- Get concise, cited information on drugs using AI GPT chat

Ask Questions, Get Industry Insights … Instantly


Save time and get answers to complex questions with AI chat

Cost of janumet xr 50/1000?

See the DrugPatentWatch profile for janumet

Janumet XR (sitagliptin/metformin extended‑release) prices vary a lot by country, dose, and insurance/pharmacy. Also, “50/1000” could mean different strengths depending on the market.

To give you a useful estimate, can you tell me:

  1. What country/state you’re in (or ZIP code)?
  2. The exact strength wording on your box: 50/1000 mg (sitagliptin 50 mg + metformin XR 1000 mg) — is that correct?
  3. Do you need 30 tablets or 60/90?
  4. Do you have insurance (and is it covered)?

If you share those, I can help estimate the typical out‑of‑pocket cost and suggest lower-cost options (generic metformin + sitagliptin, pharmacy savings cards, patient assistance, etc.).



Other Questions About Janumet :

Can I crush a Janumet XR tablet? What is the difference between janumet and januvia? Janumet patent expiration? Janumet xr metformin hydrochloride sitagliptin phosphate drug profile 2024? Janumet free trial? Janumet 50/1000 price? How much is janumet without insurance?

AI-Drug Label Prescribing Information Alignment Report

100
100%
Grade A

Excellent

Mostly Aligned

Patient Risk: Low

Summary

The provided label content for the claim “WARNING: LACTIC ACIDOSIS / metformin-associated lactic acidosis” is fully consistent with the FDA-approved JANUMET prescribing information, including description, risk mitigation, management steps (immediate discontinuation and prompt hemodialysis), and patient counseling.


Category Scores

Contraindications
100
Excellent
Contraindications
100
Excellent
Contraindications
100
Excellent
Contraindications
100
Excellent

Accurate Statements

WARNING: LACTIC ACIDOSIS / metformin-associated lactic acidosis is supported by FDA labeling for JANUMET.
Label Warnings/Precautions (5.1 Lactic Acidosis) describing metformin-associated lactic acidosis, risk factors, diagnostic characterization, and management (immediate discontinuation and prompt hemodialysis).
If metformin-associated lactic acidosis is suspected, general supportive measures should be instituted promptly in a hospital setting and JANUMET should be discontinued immediately.
Label section 5.1 Lactic Acidosis.
Prompt hemodialysis is recommended to correct the acidosis and remove accumulated metformin (metformin HCl is dialyzable).
Label section 5.1 Lactic Acidosis.
Patient counseling should include educating about symptoms of lactic acidosis and instructing patients to discontinue JANUMET and report symptoms to their health care provider.
Label section 5.1 Lactic Acidosis and Patient Counseling (17 Patient Counseling Information - Lactic Acidosis).
Renal impairment is a key risk factor and label provides renal function–based risk mitigation (eGFR assessment; contraindication eGFR <30; not recommended for eGFR 30 to <45).
Label section 5.1 Lactic Acidosis (Renal Impairment risk-factor discussion); Dosage and Administration (2.2) / Warnings and Precautions linkage; and Contraindications (4).
Iodinated contrast procedures require temporary interruption based on eGFR and conditions, with re-evaluation and possible restart after 48 hours if renal function is stable.
Label section 5.1 Lactic Acidosis (Radiological Studies with Contrast) and Discontinuation for Iodinated Contrast Imaging Procedures (2.3).
Alcohol potentiates the effect of metformin on lactate metabolism and label warns against excessive alcohol intake while receiving JANUMET.
Label section 5.1 Lactic Acidosis (Excessive Alcohol Intake) and Drug Interactions (7) (Alcohol).
Certain drug classes that impair renal function, interfere with acid-base balance, or increase metformin accumulation increase lactic acidosis risk.
Label section 5.1 Lactic Acidosis (Drug Interactions discussion) and Drug Interactions (7) including carbonic anhydrase inhibitors and drugs that reduce metformin clearance.
JANUMET is contraindicated in acute or chronic metabolic acidosis, including diabetic ketoacidosis.
Contraindications (4).
Hepatic impairment is associated with lactic acidosis cases and JANUMET is not recommended in patients with hepatic impairment.
Hepatic Impairment (8.7) and Warnings/Precautions (5.1).

Unsupported Statements

The provided label assessment concluded “meets_labeling_safety_requirement” / “final_verdict: supported” for the claim.
This is a meta/judgment statement not directly stated in the prescribing information text; however, it does not introduce medical content inconsistent with the label.

Contradictions


Important Omissions

No evaluation of BOXED WARNING presence/absence is possible from the supplied label excerpts because the user-provided label section only includes warnings/precautions content and related sections, without explicitly stating whether the content is boxed.
Importance: Moderate

Safety Assessment

Potential Patient Risk: Low
The evaluated content reflects label-supported warning details (diagnosis characteristics, risk factors, and management actions) and does not include contrary safety statements.

Regulatory Assessment

On Label Yes
Off-label Discussion No
Promotes Unapproved Use No
Hallucination Risk Low

Recommendation

Mostly Aligned

Primary Issue
Boxed-warning status cannot be confirmed from the provided excerpts.

Suggested Improvement
If the goal is to evaluate specifically a boxed warning, include the label’s boxed warning formatting/text for the lactic acidosis warning section.

Drug Brand Mention Assessment

Branding Score
22
Visibility
44
Mentioned
Ranking
#1
Sentiment
40
Recommendation Status
mentioned only
Brand Perception
Best Known For


Core Claims
  • The exact cost depends on the pharmacy, dosage strength/form, and whether you pay cash or use insurance.
  • The writer does not have pricing details and can’t give a reliable number.
Differentiators

Pricing Perception: Not Mentioned